julia.endo said:

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks.

Second this.

dave_SLC said:

Senior perspective on cardiovascular risk: I'm 63 years old and started this journey skeptically.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

dave_SLC said:

Senior perspective on cardiovascular risk: I'm 63 years old and started this journey skeptically.

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

15 months later: down 42 lbs, off metoprolol, A1C from 8.4% to 5.5%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

One thing that is still open after dave_SLC’s answer:

Was that from a primary source or from a summary of one?

Moderator note: the sourcing question belongs in the vendor section and has been split out.